Business
NFL Biosciences Outlines Its Development Plan for NFL-101 in Smoking Cessation Following Receipt of Scientific Advice From Several European Agencies and the U.S. FDA
MONTPELLIER, France, October 20, 2025--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces having received convergent and constructive scientific advice from several regulatory agencies, including the Belgian, Dutch, UK, and German authorities, as well as the U.S. FDA, as part of the development of NFL-101.
About this update from Nfl Biosciences Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Confirmation by several European agencies and the U.S. FDA of the relevance of the continuous abstinence validation criteria which showed statistical significance (p=0.02) in the Phase 2 CESTO II study","length":201,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":201,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"In Europe, a single Phase 3 trial could therefore be sufficient for the approval of NFL-101 in smoking cessation, with continuous abstinence over 12 months as the primary endpoint; in the United States, a second study in addition to the European trial will be required, with a 6-month follow-up period and a primary efficacy endpoint measured at 4 weeks","length":353,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":353,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Additional characterization and mechanism-of-action studies (CEA, HEGP, McLean/Harvard) are expected to enable the submission of clinical trial applications by mid-2026 and to meet the expectations of pharmaceutical companies","length":225,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":225,"olType":false},{"type":"text","content":"MONTPELLIER, France, October 20, 2025--(BUSINESS WIRE)--Regulatory News:","length":72,"tagName":"p"},{"type":"text","content":"NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces having received convergent and constructive scientific advice from several regulatory agencies, including the Belgian, Dutch, UK, and German authorities, as well as the U.S. FDA, as part of the development of NFL-101. The project was unanimously perceived as particularly innovative and relevant given the impact of smoking on public health.","length":568,"tagName":"p"},{"type":"text","content":"Clinical validation and efficacy criteria","length":41,"tagName":"p"},{"type":"text","content":"All agencies confirmed the relevance of validating continuous abstinence through urinary cotinine measurement, as well as the reclassification as smokers of any participants using e-cigarettes or nicotine substitutes during the study. Under...